Contents:

©2001 Adis International Inc., The Genesis Group. May not be reproduced without written permission. AUTOIMMUNE/INFLAMMATORY DISEASE COMPETITIVE STRATEGIES (2001) Edition TABLE OF CONTENTS EXECUTIVE SUMMARY.........................................................................................................................................I SECTION 1 INTRODUCTION TO AUTOIMMUNE............................................................................................ 1 1.1 SCOPE AND OBJECTIVES OF RESEARCH INVESTIGATION........................................................... 1 1.2 METHODOLOGY OF INVESTIGATION................................................................................................ 1 1.3 LIMITATIONS OF INVESTIGATION ..................................................................................................... 2 SECTION 2 COMPETITIVE BUSINESS ACTIVITY IN INFLAMMATION/AUTOIMMUNE BY INDICATION................................................................................................................................ 3 2.1 INTRODUCTION ..................................................................................................................................... 3 2.2 ANALYSIS AND FORECAST OF TOTAL INFLAMMATION/ AUTOIMMUNE MARKET AND MARKET SEGMENTS............................................................................................................................. 3 2.3 ANALYSIS AND FORECAST OF THE ASTHMA SEGMENT.............................................................. 8 2.3.1 Introduction to Pharmacologic Management of Asthma .................................................................. 8 2.3.2 Product Technology Evaluation and Forecast For Asthma ............................................................ 14 2.3.3 Competitive Developments and Implications in Asthma ............................................................... 16 2.4 ANALYSIS AND FORECAST OF THE ATHEROSCLEROSIS SEGMENT ....................................... 19 2.4.1 Introduction and Pharmacologic Management of Atherosclerosis................................................. 19 2.4.2 Product Technology Evaluation and Forecast For Atherosclerosis ................................................ 22 2.4.3 Competitive Developments and Implications in Atherosclerosis................................................... 24 2.5 ANALYSIS AND FORECAST OF THE INFLAMMATORY BOWEL DISEASE SEGMENT – CROHN’S DISEASE............................................................................................................................... 28 2.5.1 Introduction in Pharmacologic Management of Crohn’s Disease .................................................. 28 2.5.2 Product Technology Evaluation and Forecast For Crohn’s Disease............................................... 29 2.5.3 Competitive Developments in Patients in Crohn’s Disease ........................................................... 31 2.6 ANALYSIS AND FORECAST OF THE INFLAMMATORY BOWEL DISEASE SEGMENT – ULCERATIVE COLITIS ......................................................................................................................... 34 2.6.1 Introduction in Pharmacologic Management of Ulcerative Colitis ................................................ 34 2.6.2 Product Technology Evaluation and Forecast For Ulcerative Colitis............................................. 35 2.6.3 Competitive Developments and Implications in Ulcerative Colitis ............................................... 36 2.7 ANALYSIS AND FORECAST OF THE DIABETES, TYPE I SEGMENT ........................................... 39 2.7.1 Introduction in Pharmacologic Management of Diabetes Type I................................................... 39 2.7.2 Product Technology Evaluation and Forecast For Type I Diabetes ............................................... 44 2.7.3 Competitive Developments and Implications in Type I Diabetes .................................................. 48 2.8 ANALYSIS AND FORECAST OF THE GRAVES’ DISEASE SEGMENT.......................................... 52 2.8.1 Introduction in Pharmacologic Management of Graves’ Disease .................................................. 52 2.8.2 Product Technology Evaluation and Forecast For Graves’ Disease............................................... 52 2.8.3 Competitive Developments and Implications in Graves’ Disease.................................................. 53 2.9 ANALYSIS AND FORECAST OF THE IRRITABLE BOWEL SYNDROME SEGMENT ................. 55 2.9.1 Introduction in Pharmacologic Management of Irritable Bowel Syndrome................................... 55 2.9.2 Product Technology Evaluation and Forecast For Irritable Bowel Syndrome ............................... 57 2.9.3 Competitive Developments and Implications in Irritable Bowel Syndrome .................................. 58 2.10 ANALYSIS AND FORECAST OF MULTIPLE SCLEROSIS SEGMENT............................................ 61 2.10.1 Introduction and Pharmacologic Management of Multiple Sclerosis............................................. 61 2.10.2 Product Technology Evaluation and Forecast for Multiple Sclerosis............................................. 63 2.10.3 Competitive Developments and Implications in Multiple Sclerosis............................................... 65 2.11 ANALYSIS AND FORECAST OF THE MYASTHENIA GRAVIS SEGMENT................................... 67 2.11.1 Introduction in Pharmacologic Management of Myasthenia Gravis .............................................. 67 2.11.2 Product Technology Evaluation And Forecast For Myasthenia Gravis ......................................... 68 ©2001 Adis International Inc., The Genesis Group. May not be reproduced without written permission. 2.11.3 Competitive Developments and Implications in Myasthenia Gravis.............................................. 69 2.12 ANALYSIS AND FORECAST OF PSORIASIS SEGMENT ................................................................. 70 2.12.1 Introduction and Pharmacologic Management of Psoriasis............................................................ 70 2.12.2 Product Technology Evaluation and Forecast for Psoriasis ........................................................... 71 2.12.3 Competitive Developments and Implications for Psoriasis............................................................ 74 2.13 ANALYSIS AND FORECAST OF THE RHEUMATOID ARTHRITIS SEGMENT ............................ 78 2.13.1 Introduction and Pharmacologic Management of Rheumatoid Arthritis........................................ 78 2.13.2 Product Technology Evaluation and Forecast For Rheumatoid Arthritis....................................... 81 2.13.3 Competitive Developments and Implications in Rheumatoid Arthritis.......................................... 85 2.14 ANALYSIS AND FORECAST OF SCLERODERMA SEGMENT........................................................ 88 2.14.1 Introduction and Pharmacologic Management of Scleroderma...................................................... 88 2.14.2 Product Technology Evaluation and Forecast for Scleroderma ..................................................... 90 2.14.3 Competitive Developments and Implications in Scleroderma........................................................ 91 2.15 ANALYSIS AND FORECAST OF SJOGREN’S DISEASE SEGMENT............................................... 93 2.15.1 Introduction and Pharmacologic Management of Sjogren’s Disease ............................................. 93 2.15.2 Product Technology Evaluation and Forecast For Sjogren’s Disease ............................................ 94 2.15.3 Competitive Developments and Implications in Sjogren’s Syndrome ........................................... 94 2.16 ANALYSIS AND FORECAST OF THE SYSTEMIC LUPUS ERYTHEMATOSUS SEGMENT........ 96 2.16.1 Introduction and Pharmacologic Management of Systemic Lupus Erythematosus........................ 96 2.16.2 Product Technology Evaluation and Forecast for Systemic Lupus Erythematosus ....................... 97 2.16.3 Competitive Developments and Implications in Systemic Lupus Erythematosus.......................... 98 SECTION 3 PROFILES OF LEADING FIRMS DEVELOPING AND/OR MARKETING AUTOIMMUNE MEDICINES.............................................................................................................................. 101 3.1 ABBOTT................................................................................................................................................ 101 3.1.1 Executive Summary ..................................................................................................................... 101 3.1.2 Business Performance Evaluation ................................................................................................ 104 3.1.3 Autoimmune Portfolio Performance ............................................................................................ 106 3.2 AMERICAN HOME PRODUCTS......................................................................................................... 112 3.2.1 Executive Summary ..................................................................................................................... 112 3.2.2 Business Performance Evaluation ................................................................................................ 114 3.2.3 Autoimmune Portfolio Performance ............................................................................................ 116 3.3 ASTRAZENECA................................................................................................................................... 123 3.3.1 Executive Summary ..................................................................................................................... 123 3.3.2 Business Performance Evaluation ................................................................................................ 127 3.3.3 Autoimmune Portfolio Performance ............................................................................................ 128 3.4 AVENTIS............................................................................................................................................... 136 3.4.1 Executive Summary ..................................................................................................................... 136 3.4.2 Business Performance Evaluation ................................................................................................ 138 3.4.3 Autoimmune Performance............................................................................................................ 139 3.5 BAYER.................................................................................................................................................. 149 3.5.1 Executive Summary ..................................................................................................................... 149 3.5.2 Business Performance Evaluation ................................................................................................ 151 3.5.3 Autoimmune Portfolio Performance ............................................................................................ 153 3.6 BIOGEN ................................................................................................................................................ 158 3.6.1 Executive Summary ..................................................................................................................... 158 3.6.2 Business Performance Evaluation ................................................................................................ 160 3.6.3 Autoimmune Portfolio Performance ............................................................................................ 162 3.7 BRISTOL-MYERS SQUIBB ................................................................................................................. 167 3.7.1 Executive Summary ..................................................................................................................... 167 3.7.2 Business Performance Evaluation ................................................................................................ 170 3.7.3 Autoimmune Portfolio Performance ............................................................................................ 171 3.8 ELI LILLY............................................................................................................................................. 178 3.8.1 Executive Summary ..................................................................................................................... 178 3.8.2 Business Performance Evaluation ................................................................................................ 180 3.8.3 Autoimmune Portfolio Performance ............................................................................................ 182 ©2001 Adis International Inc., The Genesis Group. May not be reproduced without written permission. 3.9 GLAXOSMITHKLINE .......................................................................................................................... 187 3.9.1 Executive Summary ..................................................................................................................... 187 3.9.2 Business Performance Evaluation ................................................................................................ 190 3.9.3 Autoimmune Portfolio Performance ............................................................................................ 192 3.10 JOHNSON & JOHNSON ....................................................................................................................... 198 3.10.1 Executive Summary ..................................................................................................................... 198 3.10.2 Business Performance Evaluation ................................................................................................ 201 3.10.3 Autoimmune Portfolio Performance ............................................................................................ 204 3.11 MERCK ................................................................................................................................................. 210 3.11.1 Executive Summary ..................................................................................................................... 210 3.11.2 Business Performance Evaluation ................................................................................................ 213 3.11.3 Autoimmune Portfolio Performance ............................................................................................ 215 3.12 NOVARTIS ........................................................................................................................................... 221 3.12.1 Executive Summary ..................................................................................................................... 221 3.12.2 Business Performance Evaluation ................................................................................................ 224 3.12.3 Autoimmune Portfolio Performance ............................................................................................ 226 3.13 NOVO NORDISK ................................................................................................................................. 232 3.13.1 Executive Summary ..................................................................................................................... 232 3.13.2 Business Performance Evaluation ................................................................................................ 234 3.13.3 Autoimmune Portfolio Performance ............................................................................................ 235 3.14 PFIZER .................................................................................................................................................. 240 3.14.1 Executive Summary ..................................................................................................................... 240 3.14.2 Business Performance Evaluation ................................................................................................ 242 3.14.3 Autoimmune Portfolio Performance ............................................................................................ 243 3.15 PHARMACIA........................................................................................................................................ 254 3.15.1 Executive Summary ..................................................................................................................... 254 3.15.2 Business Performance Evaluation ................................................................................................ 256 3.15.3 Autoimmune Portfolio Performance ............................................................................................ 258 3.16 ROCHE.................................................................................................................................................. 264 3.16.1 Executive Summary ..................................................................................................................... 264 3.16.2 Business Performance Evaluation ................................................................................................ 266 3.16.3 Autoimmune Portfolio Performance ............................................................................................ 267 3.17 SCHERING-PLOUGH ........................................................................................................................... 275 3.17.1 Executive Summary ..................................................................................................................... 275 3.17.2 Business Performance Evaluation ................................................................................................ 277 3.17.3 Autoimmune Portfolio Performance ............................................................................................ 278 SECTION 4 EVALUATION OF THE LEADING FIRMS IN AUTOIMMUNE THERAPEUTICS............. 285 4.1 COMPETENCY REQUIREMENTS FOR MARKET LEADERSHIP .................................................. 285 4.1.1 Competency Requirements........................................................................................................... 285 4.1.2 Competitive Analysis of Participating Manufacturers.................................................................. 289 4.2 FIVE-YEAR SUMMARY ANALYSIS AND EVALUATION OF AUTOIMMUNE MARKET LEADING STAKEHOLDERS............................................................................................................... 292 ©2001 Adis International Inc., The Genesis Group. May not be reproduced without written permission. AUTOIMMUNE/INFLAMMATORY DISEASE COMPETITIVE STRATEGIES (2001) Edition LIST OF FIGURES Figure ES- 1 Leading Manufacturers - Forecast Sales and % Change - 2001-2005............................................. iv Figure ES- 2 Leading Manufacturers - Forecast Sales Vs % Change in Market Share - 2001-2005..................... v Figure 2.1 Forecast for Asthma Management by Technology Type................................................................ 15 Figure 2.2 Strategic Matrix –Asthma............................................................................................................... 18 Figure 2.3 Strategic Timeline - Asthma........................................................................................................... 19 Figure 2.4 Forecast for Atherosclerosis Management by Technology Type ................................................... 24 Figure 2.5 Strategic Matrix – Atherosclerosis ................................................................................................. 27 Figure 2.6 Strategic Timeline - Atherosclerosis .............................................................................................. 28 Figure 2.7 Forecast for Crohn’s Disease Management by Technology Type.................................................. 31 Figure 2.8 Strategic Matrix - Crohn’s Disease ................................................................................................ 33 Figure 2.9 Strategic Timeline - Crohn’s Disease............................................................................................. 34 Figure 2.10 Forecast for Ulcerative Colitis Disease Management by Technology Type................................... 36 Figure 2.11 Strategic Matrix – Ulcerative Colitis.............................................................................................. 38 Figure 2.12 Strategic Timeline – Ulcerative Colitis .......................................................................................... 39 Figure 2.13 Forecast for Type 1 Diabetes by Technology Type........................................................................ 47 Figure 2.14 Strategic Matrix –Type 1 Diabetes................................................................................................. 51 Figure 2.15 Strategic Timeline for Type 1 Diabetes.......................................................................................... 51 Figure 2.16 Forecast for Graves’ Disease by Technology Type........................................................................ 53 Figure 2.17 Strategic Matrix – Graves’ Disease ................................................................................................ 54 Figure 2.18 Strategic Timeline – Graves’ Disease ............................................................................................ 55 Figure 2.19 Forecast for Irritable Bowel Syndrome by Technology Type ........................................................ 58 Figure 2.20 Strategic Matrix – Irritable Bowel Syndrome ................................................................................ 60 Figure 2.21 Strategic Timeline– Irritable Bowel Syndrome.............................................................................. 60 Figure 2.22 Forecast for Multiple Sclerosis by Technology Type..................................................................... 64 Figure 2.23 Strategic Matrix - Multiple Sclerosis.............................................................................................. 66 Figure 2.24 Strategic Timeline- Multiple Sclerosis ........................................................................................... 67 Figure 2.25 Forecast for Myasthenia Gravis by Technology Type.................................................................... 69 Figure 2.26 Forecast for Psoriasis By Technology Type................................................................................... 73 Figure 2.27 Strategic Matrix - Psoriasis ............................................................................................................ 77 Figure 2.28 Strategic Timeline - Psoriasis......................................................................................................... 77 Figure 2.29 Forecast for Rheumatoid Arthritis by Technology Type................................................................ 84 Figure 2.30 Strategic Matrix – Rheumatoid Arthritis ........................................................................................ 87 Figure 2.31 Strategic Timeline – Rheumatoid Arthritis..................................................................................... 88 Figure 2.32 Forecast for Scleroderma by Technology Type.............................................................................. 91 Figure 2.33 Strategic Matrix - Scleroderma....................................................................................................... 92 Figure 2.34 Strategic Timeline - Scleroderma ................................................................................................... 92 Figure 2.35 Forecast for Sjogren’s Syndrome by Technology Type ................................................................. 94 Figure 2.36 Strategic Matrix – Sjorgren’s Syndrome ........................................................................................ 95 Figure 2.37 Forecast for Systemic Lupus Erythematosus by Technology Type................................................ 98 Figure 2.38 Strategic Matrix - Systemic Lupus Erythematosus ........................................................................ 99 Figure 2.39 Strategic Timeline - Systemic Lupus Erythematosus ................................................................... 100 Figure 3.1 Technology Utilization – Abbott in Comparison to Industry ....................................................... 103 Figure 3.2 Abbott Product Pipeline Comparative Distribution by Development Phase ................................ 110 Figure 3.3 Technology Utilization – American Home Products in Comparison to Industry......................... 114 Figure 3.4 American Home Products Product Pipeline Comparative Distribution by Development Phase .. 120 Figure 3.5 Technology Utilization – AstraZeneca in Comparison to Industry .............................................. 126 Figure 3.6 AstraZeneca Product Pipeline Comparative Distribution by Development Phase ....................... 131 ©2001 Adis International Inc., The Genesis Group. May not be reproduced without written permission. Figure 3.7 Technology Utilization – Aventis in Comparison to Industry...................................................... 138 Figure 3.8 Aventis Product Pipeline Comparative Distribution by Development Phase............................... 145 Figure 3.9 Technology Utilization – Bayer in Comparison to Industry......................................................... 150 Figure 3.10 Bayer Product Pipeline Comparative Distribution by Development Phase.................................. 156 Figure 3.11 Technology Utilization – Biogen in Comparison to Industry....................................................... 160 Figure 3.12 Biogen Product Pipeline Comparative Distribution by Development Phase................................ 165 Figure 3.13 Technology Utilization – Bristol-Myers Squibb in Comparison to Industry................................ 169 Figure 3.14 Bristol-Myers Squibb Product Pipeline Comparative Distribution by Development Phase......... 173 Figure 3.15 Technology Utilization – Eli Lilly in Comparison to Industry..................................................... 180 Figure 3.16 Eli Lilly Product Pipeline Comparative Distribution by Development Phase.............................. 185 Figure 3.17 Technology Utilization – GlaxoSmithKline in Comparison to Industry ...................................... 189 Figure 3.18 Product Pipeline Comparative Distribution by Development Phase ............................................ 196 Figure 3.19 Technology Utilization – Johnson & Johnson in Comparison to Industry ................................... 201 Figure 3.20 Johnson & Johnson Product Pipeline Comparative Distribution by Development Phase ............ 207 Figure 3.21 Technology Utilization – Merck in Comparison to Industry........................................................ 212 Figure 3.22 Merck Product Pipeline Comparative Distribution by Development Phase................................. 217 Figure 3.23 Technology Utilization – Novartis in Comparison to Industry .................................................... 223 Figure 3.24 Novartis Product Pipeline Comparative Distribution by Development Phase.............................. 229 Figure 3.25 Technology Utilization – Novo Nordisk in Comparison to Industry............................................ 234 Figure 3.26 Product Pipeline Comparative Distribution by Development Phase ............................................ 238 Figure 3.27 Technology Utilization – Pfizer in Comparison to Industry......................................................... 241 Figure 3.28 Product Pipeline Comparative Distribution by Development Phase ............................................ 248 Figure 3.29 Technology Utilization – Pharmacia in Comparison to Industry ................................................. 256 Figure 3.30 Product Pipeline Comparative Distribution by Development Phase ............................................ 261 Figure 3.31 Technology Utilization – Roche in Comparison to Industry........................................................ 265 Figure 3.32 Roche Product Pipeline Comparative Distribution by Development Phase ................................. 271 Figure 3.33 Technology Utilization – Schering-Plough in Comparison to Industry ....................................... 277 Figure 3.34 Schering-Plough Product Pipeline Comparative Distribution by Development Phase................. 282 Figure 4.1 Forecast Sales and % Change - 2000-2005 .................................................................................. 295 Figure 4.2 Leading Manufacturers - Forecast Sales vs. % Change in Market Share - 2000-2005................. 296 AUTOIMMUNE/INFLAMMATORY DISEASE COMPETITIVE STRATEGIES (2001) Edition LIST OF TABLES Table ES- 1 US Market Historic and Forecast Autoimmune Sales by Indication ................................................ ii Table ES- 2 US Historic and Forecast Autoimmune Sales By Leading Firm..................................................... vi Table ES- 3 US Market Historic and Forecast Autoimmune Sales by Leading Firm ..................................... xviii Table 2.1 Historic and Forecast Sales – Autoimmune Disorders ..................................................................... 4 Table 2.2 Programs in Development – All Indications .................................................................................... 6 Table 2.3 New Product Launches 1997-2005 – All Indications....................................................................... 7 Table 2.4 Historic and Forecast Sales by Technology - Asthma.................................................................... 16 Table 2.5 New Product Launches 1997-2005 - Asthma................................................................................. 17 Table 2.6 Historic and Forecast Sales by Firm - Asthma ............................................................................... 18 Table 2.7 Programs in Development – Atherosclerosis ................................................................................. 23 Table 2.8 Historic and Forecast Sales by Technology - Atherosclerosis........................................................ 25 Table 2.9 New Product Launches 1997-2005 - Atherosclerosis..................................................................... 25 Table 2.10 Historic and Forecast Sales by Firm - Atherosclerosis................................................................... 26 Table 2.11 Programs in Development – Crohn’s Disease ................................................................................ 30 Table 2.12 Historic and Forecast Sales by Technology - Crohn’s Disease ...................................................... 32 Table 2.13 New Product Launches 1997-2005 - Crohn’s Disease ................................................................... 32 Table 2.14 Historic and Forecast Sales by Firm - Crohn’s Disease ................................................................. 33 Table 2.15 Programs in Development – Ulcerative Colitis .............................................................................. 36 Table 2.16 Historic and Forecast Sales by Technology Firm - Ulcerative Colitis ........................................... 37 Table 2.17 New Product Launches 1997-2005 - Ulcerative Colitis ................................................................. 37 Table 2.18 Historic and Forecast Sales by Firm - Ulcerative Colitis ............................................................... 37 Table 2.19 Programs in Development Diabetes Type 1 ................................................................................... 47 Table 2.20 Historic and Forecast Sales by Technology - Type 1 Diabetes ...................................................... 48 Table 2.21 New Product Launches 1997-2005 – Type 1 Diabetes................................................................... 49 Table 2.22 Historic and Forecast Sales by Lead Manufacturer – Type 1 Diabetes .......................................... 50 Table 2.23 Programs in Development – Graves’ Disease ................................................................................ 53 Table 2.24 Historic and Forecast Sales by Technology - Graves’ Disease ...................................................... 54 Table 2.25 Historic and Forecast Sales by Firm - Graves’ Disease.................................................................. 54 Table 2.26 Programs in Development – Irritable Bowel Syndrome................................................................. 57 Table 2.27 Historic and Forecast Sales by Technology - Irritable Bowel Syndrome....................................... 58 Table 2.28 New Product Launches 1997-2005 - Irritable Bowel Syndrome.................................................... 59 Table 2.29 Historic and Forecast Sales by Firm - Irritable Bowel Syndrome .................................................. 59 Table 2.30 Programs in Development – Multiple Sclerosis ............................................................................. 64 Table 2.31 Historic and Forecast Sales by Technology - Multiple Sclerosis ................................................... 65 Table 2.32 New Product Launches 1997-2005 - Multiple Sclerosis ................................................................ 65 Table 2.33 Historic and Forecast Sales by Firm - Multiple Sclerosis .............................................................. 66 Table 2.34 Programs in Development - Myasthenia Gravis............................................................................. 68 Table 2.35 Historic and Forecast Sales by Technology - Myasthenia Gravis .................................................. 69 Table 2.36 Programs in Development - Psoriasis............................................................................................. 72 Table 2.37 Historic and Forecast Sales by Technology.................................................................................... 74 Table 2.38 New Product Launches 1997-2005................................................................................................. 75 Table 2.39 Historic and Forecast Sales by Firm............................................................................................... 76 Table 2.40 Programs in Development – Rheumatoid Arthritis ........................................................................ 84 Table 2.41 Historic and Forecast Sales by Technology – Rheumatoid Arthritis.............................................. 85 Table 2.42 New Product Launches 1997-2005 – Rheumatoid Arthritis........................................................... 86 Table 2.43 Historic and Forecast Sales by Firm – Rheumatoid Arthritis ......................................................... 86 Table 2.44 Programs in Development - Scleroderma....................................................................................... 90 Table 2.45 Historic and Forecast Sales by Technology - Scleroderma ............................................................ 91 Table 2.46 Historic and Forecast Sales by Firm - Scleroderma ....................................................................... 91 ©2001 Adis International Inc., The Genesis Group. May not be reproduced without written permission. Table 2.47 Programs in Development - Sjogren’s Disease .............................................................................. 94 Table 2.48 Historic and Forecast Sales by Technology - Sjogren’s Disease.................................................... 94 Table 2.49 New Product Launches 1997-2005 - Sjogren’s Disease................................................................. 95 Table 2.50 Historic and Forecast Sales by Firm - Sjogren’s Disease............................................................... 95 Table 2.51 Programs in Development - Systemic Lupus Erythematosus......................................................... 97 Table 2.52 Historic and Forecast Sales by Technology - Systemic Lupus Erythematosus .............................. 98 Table 2.53 New Product Launches 1997-2005 - Systemic Lupus Erythematosus ........................................... 98 Table 2.54 Historic and Forecast Sales by Firm - Systemic Lupus Erythematosus ......................................... 99 Table 4.1 Manufacturer Drug Sales, Key Brands and New Product Development Pipeline........................ 286 Table 4.2 Pharmaceutical Research & Development - % 0f Total Worldwide Sales................................... 287 Table 4.3 R&D Expenditures in Autoimmune Therapeutics........................................................................ 288 Table 4.4 Patent Exposure in Autoimmune Therapeutics– 2000-2005 ........................................................ 288 Table 4.5 Business Development Activity in Autoimmune Therapeutics.................................................... 289 Table 4.6 Leading Firms Sales Force Size ................................................................................................... 289 Table 4.7 Historic and Forecast Autoimmune Sales by Indication .............................................................. 290 Table 4.8 New Product Launch Activity – Significant Brands on Market 1997-2005................................. 291 Table 4.9 Product Development Programs by Indication and Status ........................................................... 291 Table 4.10 Rank by Company Share of Autoimmune Clinical Pipeline ........................................................ 292 Table 4.11 Summary Analysis Leading Stakeholders – Autoimmune Therapeutics...................................... 292 Table 4.12 Historic and Forecast Sales by Manufacturer............................................................................... 293 Table 4.13 Leading Firms – Sales Performance and Market Trends 2005..................................................... 294 List of Charts Chart 3.1.1 Summary of Abbott’s Autoimmune Development Activity......................................................... 102 Chart 3.1.2 Abbott’s Projected Therapeutic System Sales & Market Shares by Market Segment ................. 103 Chart 3.1.3 Number of Abbott’s Reported Clinical Development Programs by Indication Group................. 105 Chart 3.1.4 Abbott Autoimmune Sales by Indication ..................................................................................... 106 Chart 3.1.5 Abbott US Autoimmune Pharmaceuticals Historical Sales by Brand .......................................... 106 Chart 3.1.6 Abbott Autoimmune Strategic Alliances and Mergers................................................................. 109 Chart 3.1.7 Abbott Summary Autoimmune Development Activity Comparison to Industry ......................... 110 Chart 3.1.8 Abbott Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform............................................................................................................. 111 Chart 3.1.9 Abbott Asthma Development Activity Comparison to Industry .................................................. 111 Chart 3.1.10 Abbott Atherosclerosis Development Activity Comparison to Industry...................................... 111 Chart 3.1.11 Abbott Psoriasis Development Activity Comparison to Industry................................................. 112 Chart 3.1.12 Abbott RA Development Activity Comparison to Industry ......................................................... 112 Chart 3.2.1 Summary of American Home Products’ Autoimmune Development Activity ............................ 113 Chart 3.2.2 AHP’s Projected Sales & Market Shares by Market Segment ..................................................... 114 Chart 3.2.3 Number of American Home Products’ Reported Clinical Development Programs by Indication Group.......................................................................................................................... 115 Chart 3.2.4 AHP Autoimmune Sales by Indication ........................................................................................ 117 Chart 3.2.5 American Home Products US Autoimmune Pharmaceuticals Historical Sales by Brand............ 117 Chart 3.2.6 American Home Products Autoimmune Strategic Alliances and Mergers................................... 119 Chart 3.2.7 AHP Summary Autoimmune Development Activity Comparison to Industry ............................ 119 Chart 3.2.8 AHP Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform............................................................................................................. 120 Chart 3.2.9 American Home Products Crohn’s Disease Development Activity Comparison to Industry ...... 121 Chart 3.2.10 American Home Products Psoriasis Development Activity Comparison to Industry .................. 121 Chart 3.2.11 American Home Products RA Development Activity Comparison to Industry........................... 122 Chart 3.2.12 American Home Products Ulcerative Colitis Development Activity Comparison to Industry .... 123 Chart 3.2.13 American Home Products Unspecified Development Activity Comparison to Industry ............. 123 Chart 3.3.1 Summary of AstraZeneca’s Autoimmune Development Activity................................................ 125 Chart 3.3.2 AstraZeneca’s Projected Sales & Market Shares by Market Segment ......................................... 126 Chart 3.3.3 Number of AstraZeneca’s Reported Clinical Development Programs by Indication Group........ 128 Chart 3.3.4 AstraZeneca Autoimmune Sales by Indication ............................................................................ 128 Chart 3.3.5 AstraZeneca US Autoimmune Pharmaceuticals Historical Sales by Brand ................................. 129 Chart 3.3.6 AstraZeneca Autoimmune Strategic Alliances and Mergers........................................................ 130 Chart 3.3.7 AstraZeneca Summary Autoimmune Development Activity Comparison to Industry ................ 130 Chart 3.3.8 AstraZeneca Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform....................................................................................... 131 Chart 3.3.9 AstraZeneca Number of Product Development Programs in Asthma by Phase of Development 133 Chart 3.3.10 AstraZeneca Number of Product Development Programs in Atherosclerosis by Phase of Development ............................................................................................................................... 134 Chart 3.3.11 AstraZeneca Number of Product Development Programs in MS by Phase of Development....... 134 Chart 3.3.12 AstraZeneca Number of Product Development Programs in RA by Phase of Development ....... 135 Chart 3.3.13 AstraZeneca Number of Product Development Programs in Type I Diabetes by Phase of Development ............................................................................................................................... 135 Chart 3.3.14 AstraZeneca Number of Product Development Programs Unspecified by Phase of Development ............................................................................................................................... 135 Chart 3.4.1 Summary of Aventis’ Autoimmune Development Activity ......................................................... 136 Chart 3.4.2 Aventis’ Projected Sales & Market Shares by Market Segment .................................................. 137 Chart 3.4.3 Number of Aventis’ Reported Clinical Development Programs by Indication Group ................. 139 Chart 3.4.4 Aventis Autoimmune Sales by Indication .................................................................................... 140 ©2001 Adis International Inc., The Genesis Group. May not be reproduced without written permission. Chart 3.4.5 Aventis US Autoimmune Pharmaceuticals Historical Sales by Brand......................................... 141 Chart 3.4.6 Aventis Autoimmune Strategic Alliances and Mergers ............................................................... 144 Chart 3.4.7 Aventis Summary Autoimmune Development Activity Comparison to Industry........................ 144 Chart 3.4.8 Aventis Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform....................................................................................... 145 Chart 3.4.9 Aventis Asthma Development Activity Comparison to Industry................................................. 146 Chart 3.4.10 Aventis Atherosclerosis Development Activity Comparison to Industry..................................... 147 Chart 3.4.11 Aventis RA Development Activity Comparison to Industry........................................................ 148 Chart 3.4.12 Aventis SLE Development Activity Comparison to Industry ...................................................... 148 Chart 3.4.13 Aventis Type I Diabetes Development Activity Comparison to Industry .................................... 149 Chart 3.5.1 Summary of Bayer’s Autoimmune Development Activity .......................................................... 150 Chart 3.5.2 Bayer’s Projected Therapeutic System Sales & Market Shares by Market Segment ................... 150 Chart 3.5.3 Bayer’s Number of Reported Development Programs by Indication Group................................ 152 Chart 3.5.4 Bayer Autoimmune Sales by Indication ....................................................................................... 153 Chart 3.5.5 Bayer US Autoimmune Pharmaceuticals Historical Sales by Brand............................................ 153 Chart 3.5.6 Bayer Autoimmune Strategic Alliances and Mergers .................................................................. 155 Chart 3.5.7 Bayer Summary Autoimmune Development Activity Comparison to Industry........................... 156 Chart 3.5.8 Bayer Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform............................................................................................................. 157 Chart 3.5.9 Bayer Asthma Development Activity Comparison to Industry.................................................... 157 Chart 3.5.10 Bayer Atherosclerosis Development Activity Comparison to Industry........................................ 158 Chart 3.5.11 Bayer MS Development Activity Comparison to Industry .......................................................... 158 Chart 3.6.1 Summary of Biogen’s Autoimmune Development Activity ........................................................ 159 Chart 3.6.2 Biogen’s Projected Therapeutic System Sales & Market Shares by Market Segment ................. 159 Chart 3.6.3 Number of Biogen’s Reported Clinical Development Programs by Indication Group ................ 162 Chart 3.6.4 Biogen Autoimmune Sales by Indication ..................................................................................... 162 Chart 3.6.5 Biogen US Autoimmune Pharmaceuticals Historical Sales by Brand.......................................... 163 Chart 3.6.6 Biogen Autoimmune Strategic Alliances and Mergers ................................................................ 164 Chart 3.6.7 Biogen Summary Autoimmune Development Activity Comparison to Industry......................... 165 Chart 3.6.8 Biogen Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform............................................................................................................. 165 Chart 3.6.9 Biogen Asthma Development Activity Comparison to Industry.................................................. 166 Chart 3.6.10 Biogen Atherosclerosis Development Activity Comparison to Industry...................................... 166 Chart 3.6.11 Biogen Crohn’s Disease Development Activity Comparison to Industry .................................... 166 Chart 3.6.12 Biogen MS Development Activity Comparison to Industry......................................................... 167 Chart 3.6.13 Biogen Psoriasis Development Activity Comparison to Industry ................................................ 167 Chart 3.6.14 Biogen RA Development Activity Comparison to Industry......................................................... 167 Chart 3.7.1 Summary of Bristol-Myers Squibb’s Autoimmune Development Activity ................................. 168 Chart 3.7.2 Bristol-Myers Squibb’s Projected Sales & Market Shares by Market Segment........................... 169 Chart 3.7.3 Number of Bristol-Myers Squibb’s Reported Clinical Development Programs by Indication Group........................................................................................................................................... 171 Chart 3.7.4 Bristol-Myers Squibb Autoimmune Sales by Indication.............................................................. 171 Chart 3.7.5 Bristol-Myers Squibb US Autoimmune Pharmaceuticals Historical Sales by Brand................... 172 Chart 3.7.6 BMS Autoimmune Strategic Alliances and Mergers ................................................................... 172 Chart 3.7.7 Bristol-Myers Squibb Summary Autoimmune Development Activity Comparison to Industry.. 173 Chart 3.7.8 Bristol-Myers Squibb Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform................................................................................... 174 Chart 3.7.9 Bristol-Myers Squibb Asthma Development Activity Comparison to Industry........................... 174 Chart 3.7.10 Bristol-Myers Squibb Atherosclerosis Development Activity Comparison to Industry............... 175 Chart 3.7.11 Bristol-Myers Squibb Crohn’s Disease Development Activity Comparison to Industry ............. 176 Chart 3.7.12 Bristol-Myers Squibb IBS Development Activity Comparison to Industry ................................. 176 Chart 3.7.13 Bristol-Myers Squibb Psoriasis Development Activity Comparison to Industry ......................... 177 Chart 3.7.14 Bristol-Myers Squibb RA Development Activity Comparison to Industry.................................. 177 Chart 3.7.15 Bristol-Myers Squibb SLE Development Activity Comparison to Industry ................................ 177 Chart 3.7.16 Bristol-Myers Squibb Type I Diabetes Development Activity Comparison to Industry.............. 178 Chart 3.8.1 Summary of Eli Lilly’s Autoimmune Development Activity....................................................... 179 Chart 3.8.2 Eli Lilly’s Projected Sales & Market Shares by Market Segment................................................ 179 Chart 3.8.3 Number of Eli Lilly’s Reported Clinical Development Programs by Indication Group .............. 181 Chart 3.8.4 Eli Lilly Autoimmune Sales by Indication ................................................................................... 182 Chart 3.8.5 Eli Lilly US Autoimmune Pharmaceuticals Historical Sales by Brand........................................ 182 Chart 3.8.6 Eli Lilly Autoimmune Strategic Alliances and Mergers .............................................................. 184 Chart 3.8.7 Eli Lilly Summary Autoimmune Development Activity Comparison to Industry....................... 184 Chart 3.8.8 Eli Lilly Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform....................................................................................... 185 Chart 3.8.9 Eli Lilly Asthma Development Activity Comparison to Industry................................................ 186 Chart 3.8.10 Eli Lilly Atherosclerosis Development Activity Comparison to Industry.................................... 186 Chart 3.8.11 Eli Lilly Crohn’s Disease Development Activity Comparison to Industry .................................. 187 Chart 3.8.12 Eli Lilly Type I Diabetes Development Activity Comparison to Industry................................... 187 Chart 3.9.1 Summary of GlaxoSmithKline Autoimmune Development Activity........................................... 188 Chart 3.9.2 GlaxoSmithKline’s Projected Sales & Market Shares by Market Segment ................................. 189 Chart 3.9.3 Number of GlaxoSmithKline Reported Clinical Development Programs by Indication Group... 191 Chart 3.9.4 GlaxoSmithKline Autoimmune Sales by Indication .................................................................... 192 Chart 3.9.5 GlaxoSmithKline US Autoimmune Pharmaceuticals Historical Sales by Brand ......................... 193 Chart 3.9.6 GlaxoSmithKline Autoimmune Strategic Alliances and Mergers................................................ 195 Chart 3.9.7 GlaxoSmithKline Summary Autoimmune Development Activity Comparison to Industry ........ 195 Chart 3.9.8 GlaxoSmithKline Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform....................................................................................... 196 Chart 3.9.9 GlaxoSmithKline Atherosclerosis Development Activity Comparison to Industry..................... 197 Chart 3.9.10 GlaxoSmithKline Psoriasis Development Activity Comparison to Industry................................ 198 Chart 3.9.11 GlaxoSmithKline Ulcerative Colitis Development Activity Comparison to Industry.................. 198 Chart 3.10.1 Summary of Johnson & Johnson’s Autoimmune Development Activity..................................... 200 Chart 3.10.2 Johnson & Johnson’s Projected Sales & Market Shares by Market Segment .............................. 200 Chart 3.10.3 Number of Johnson & Johnson’s Reported Clinical Development Programs by Indication Group........................................................................................................................................... 203 Chart 3.10.4 Johnson & Johnson Autoimmune Sales by Indication ................................................................. 204 Chart 3.10.5 Johnson & Johnson US Autoimmune Pharmaceuticals Historical Sales by Brand ...................... 205 Chart 3.10.6 Johnson & Johnson Autoimmune Strategic Alliances and Mergers............................................. 206 Chart 3.10.7 Johnson & Johnson Summary Autoimmune Development Activity Comparison to Industry ..... 206 Chart 3.10.8 Johnson & Johnson Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform....................................................................................... 207 Chart 3.10.9 Johnson & Johnson Crohn’s Disease Development Activity Comparison to Industry ................ 208 Chart 3.10.10 Johnson & Johnson IBS Development Activity Comparison to Industry .................................... 208 Chart 3.10.11 Johnson & Johnson Psoriasis Development Activity Comparison to Industry ............................ 209 Chart 3.10.12 Johnson & Johnson RA Development Activity Comparison to Industry ..................................... 209 Chart 3.10.13 Johnson & Johnson Type I Development Activity Comparison to Industry ................................ 210 Chart 3.10.14 Johnson & Johnson Unspecified Development Activity Comparison to Industry ....................... 210 Chart 3.11.1 Summary of Merck’s Autoimmune Development Activity.......................................................... 211 Chart 3.11.2 Merck’s Projected Sales & Market Shares by Market Segment................................................... 212 Chart 3.11.3 Number of Merck’s Reported Clinical Development Programs by Indication Group ................. 215 Chart 3.11.4 Merck Autoimmune Sales by Indication ...................................................................................... 215 Chart 3.11.5 Merck US Autoimmune Pharmaceuticals Historical Sales by Brand........................................... 216 Chart 3.11.6 Merck Summary Autoimmune Development Activity Comparison to Industry.......................... 217 Chart 3.11.7 Merck Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform............................................................................................................. 218 Chart 3.11.8 Merck Asthma Development Activity Comparison to Industry ................................................... 218 Chart 3.11.9 Merck Atherosclerosis Development Activity Comparison to Industry....................................... 219 Chart 3.11.10 Merck Grave’s Disease Development Activity Comparison to Industry ..................................... 219 Chart 3.11.11 Merck RA Development Activity Comparison to Industry.......................................................... 220 Chart 3.11.12 Merck Type I Development Activity Comparison to Industry..................................................... 221 Chart 3.12.1 Summary of Novartis’ Autoimmune Development Activity Versus the Competition ................. 222 Chart 3.12.2 Novartis’ Projected Sales & Market Shares by Market Segment ................................................. 223 Chart 3.12.3 Novartis Number of Reported Number of Clinical Development Programs by Indication Group........................................................................................................................................... 225 Chart 3.12.4 Novartis Autoimmune Sales by Indication................................................................................... 226 Chart 3.12.5 Novartis US Autoimmune Pharmaceuticals Historical Sales by Brand ....................................... 226 Chart 3.12.6 Novartis Autoimmune Strategic Alliances and Mergers .............................................................. 228 Chart 3.12.7 Novartis Summary Autoimmune Development Activity Comparison to Industry....................... 228 Chart 3.12.8 Novartis Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform....................................................................................... 229 Chart 3.12.9 Novartis Asthma Development Activity Comparison to Industry................................................ 230 Chart 3.12.10 Novartis Psoriasis Development Activity Comparison to Industry.............................................. 230 Chart 3.12.11 Novartis RA Development Activity Comparison to Industry....................................................... 231 Chart 3.12.12 Novartis Unspecified Development Activity Comparison to Industry......................................... 232 Chart 3.13.1 Summary of Novo Nordisk’s Autoimmune Development Activity ............................................. 233 Chart 3.13.2 Novo Nordisk’s Projected Sales & Market Shares by Market Segment....................................... 233 Chart 3.13.3 Number of Novo Nordisk’s Reported Clinical Development Programs by Indication Group ..... 235 Chart 3.13.4 Novo Nordisk Autoimmune Sales by Indication.......................................................................... 235 Chart 3.13.5 Novo Nordisk US Autoimmune Pharmaceuticals Historical Sales by Brand .............................. 236 Chart 3.13.6 Novo Nordisk Autoimmune Strategic Alliances and Mergers ..................................................... 237 Chart 3.13.7 Novo Nordisk Summary Autoimmune Development Activity Comparison to Industry.............. 238 Chart 3.13.8 Novo Nordisk Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform....................................................................................... 238 Chart 3.13.9 Novo Nordisk SLE Development Activity Comparison to Industry ............................................ 239 Chart 3.13.10 Novo Nordisk Type I Development Activity Comparison to Industry......................................... 240 Chart 3.14.1 Summary of Pfizer’s Autoimmune Development Activity .......................................................... 240 Chart 3.14.2 Pfizer’s Projected Sales & Market Shares by Market Segment.................................................... 241 Chart 3.14.3 Number of Pfizer’s Reported Clinical Development Programs by Indication Group .................. 243 Chart 3.14.4 Pfizer Autoimmune Sales by Indication ....................................................................................... 243 Chart 3.14.5 Pfizer US Autoimmune Pharmaceuticals Historical Sales by Brand............................................ 244 Chart 3.14.6 Pfizer Autoimmune Strategic Alliances and Mergers .................................................................. 246 Chart 3.14.7 Pfizer Summary Autoimmune Development Activity Comparison to Industry........................... 247 Chart 3.14.8 Pfizer Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform............................................................................................................. 248 Chart 3.14.9 Pfizer Asthma Development Activity Comparison to Industry.................................................... 249 Chart 3.14.10 Pfizer Atherosclerosis Development Activity Comparison to Industry........................................ 251 Chart 3.14.11 Pfizer MS Development Activity Comparison to Industry .......................................................... 251 Chart 3.14.12 Pfizer Psoriasis Development Activity Comparison to Industry .................................................. 252 Chart 3.14.13 Pfizer RA Development Activity Comparison to Industry........................................................... 253 Chart 3.14.14 Pfizer Type I Development Activity Comparison to Industry...................................................... 253 Chart 3.14.15 Pfizer Ulcerative Colitis Development Activity Comparison to Industry .................................... 254 Chart 3.15.1 Summary of Pharmacia’s Autoimmune Development Activity ................................................... 255 Chart 3.15.2 Pharmacia’s Projected Sales & Market Shares by Market Segment ............................................ 255 Chart 3.15.3 Number of Pharmacia’s Reported Clinical Development Programs by Indication Group ........... 257 Chart 3.15.4 Pharmacia’s Autoimmune Sales by Indication............................................................................. 258 Chart 3.15.5 Pharmacia’s US Autoimmune Pharmaceuticals Historical Sales by Brand ................................. 259 Chart 3.15.6 Pharmacia Autoimmune Strategic Alliances and Mergers ........................................................... 260 Chart 3.15.7 Pharmacia Summary Autoimmune Development Activity Comparison to Industry.................... 260 Chart 3.15.8 Pharmacia Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform....................................................................................... 261 Chart 3.15.9 Pharmacia Atherosclerosis Development Activity Comparison to Industry ................................ 262 Chart 3.15.10 Pharmacia Crohn’s Disease Development Activity Comparison to Industry............................... 262 Chart 3.15.11 Pharmacia Psoriasis Development Activity Comparison to Industry........................................... 263 Chart 3.15.12 Pharmacia RA Development Activity Comparison to Industry ................................................... 263 Chart 3.15.13 Pharmacia Type I Development Activity Comparison to Industry .............................................. 263 Chart 3.16.1 Summary of Roche’s Autoimmune Development Activity.......................................................... 265 Chart 3.16.2 Roche’s Projected Sales & Market Shares by Market Segment ................................................... 265 Chart 3.16.3 Number of Roche’s Reported Clinical Development Programs by Indication Group.................. 267 Chart 3.16.4 Roche Autoimmune Sales by Indication ...................................................................................... 268 Chart 3.16.5 Roche US Autoimmune Pharmaceuticals Historical Sales by Brand........................................... 268 Chart 3.16.6 Roche Autoimmune Strategic Alliances and Mergers.................................................................. 270 Chart 3.16.7 Roche Summary Autoimmune Development Activity Comparison to Industry .......................... 270 Chart 3.16.8 Roche Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform............................................................................................................. 271 Chart 3.16.9 Roche Asthma Development Activity Comparison to Industry ................................................... 272 Chart 3.16.10 Roche Atherosclerosis Development Activity Comparison to Industry....................................... 273 Chart 3.16.11 Roche Crohn’s Disease Development Activity Comparison to Industry ..................................... 273 Chart 3.16.12 Roche Psoriasis Development Activity Comparison to Industry ................................................. 274 Chart 3.16.13 Roche RA Development Activity Comparison to Industry .......................................................... 274 Chart 3.16.14 Roche Type I Development Activity Comparison to Industry ..................................................... 275 Chart 3.17.1 Summary of Schering-Plough’s Dermatology Development Activity ......................................... 276 Table 3.17.2 Schering-Plough’s Projected Therapeutic System Sales & Market Shares by Market Segment.. 276 Chart 3.17.3 Number of Schering-Plough’s Reported Clinical Development Programs by Indication Group . 278 Chart 3.17.4 Schering-Plough Autoimmune Sales by Indication...................................................................... 279 Chart 3.17.5 Schering-Plough US Autoimmune Pharmaceuticals Historical Sales by Brand .......................... 279 Chart 3.17.6 Schering-Plough Autoimmune Strategic Alliances and Mergers ................................................. 281 Chart 3.17.7 Schering-Plough Number of Product Development Programs in Autoimmune by Phase of Development and Technology Platform....................................................................................... 282 Chart 3.17.8 Schering-Plough Summary Autoimmune Development Activity Comparison to Industry.......... 282 Chart 3.17.9 Schering-Plough Asthma Development Activity Comparison to Industry................................... 283 Chart 3.17.10 Schering-Plough Atherosclerosis Development Activity Comparison to Industry ...................... 283 Chart 3.17.11 Schering-Plough Psoriasis Development Activity Comparison to Industry................................. 284 Chart 3.17.12 Schering-Plough RA Development Activity Comparison to Industry.......................................... 284 Chart 3.17.13 Schering-Plough Unspecified Development Activity Comparison to Industry............................ 284

Summary:

Inflammation and autoimmune disorders include some of the largest and most dynamic segments of the pharmaceutical industry. Disease such as type 1 diabetes, asthma, atherosclerosis, rheumatoid arthritis and psoriasis represent serious and often life-threatening conditions for which there are clear and pressing therapeutic needs.